| Revenue Growth | Total revenue increased 70% year-over-year to $5.1 billion in Q3. |
|---|---|
| Mgmt Confidence | High confidence in 2027 margin expansion and long-term $4 EPS target. |
| Demand Visibility | Expect stable 2027 ACA marketplace; 850,000 lives available from competitor exits. |
| Margin Trends | Operating margin improved 780 bps; MLR improved 450 bps to 84%. |
| Op. Leverage | SG&A ratio hit record low 14% via AI and fixed-cost leverage. |
| Pricing Power | Weighted average rate increase of 14% for 2027 to drive margins. |
| Vol vs Price | Growth driven by both 27% membership increase and disciplined rate increases. |
| Segment Growth | Individual market stable; expansion into South Carolina and 713 total markets. |
| New Clients | Allstate Health Solutions partnership; expanding High-Deductible Health product into three states. |
| Capex & Debt | $9 billion cash/investments; $1.4 billion excess capital in insurance subsidiaries. |
| Regulatory | CMS program integrity reviews driving disenrollments; monitoring 2028 subsidy legislative outlook. |
| Commentary | Focus on 'progressively eliminating failure' through technology-powered support and clinical reviews. |
| New Launches | Launched Retire Ease for early retirees and Hello Menno for women. |
Growth
Total revenue grew 70% year-over-year to $5.1 billion; membership increased 27% to 2.7 million.
Outlook
Raised 2026 operating earnings guidance to $850M-$950M; targeting $4 EPS by 2029.
Risks
CMS eligibility reviews caused disenrollments; management pivoted on specific Q4 SG&A step-up drivers beyond seasonal investments.
The company's earnings call, NYSE: OSCR, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Oscar Health, Inc.: key numbers
- Share price
- $31.33Close, Nov 16
- Sector
- Finance
- Industry
- Hospital & Medical Service PlansSIC 6324
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Oscar Health, Inc.
All →Oscar Health Leadership Change
Oscar Health appointed Tomer Cohen, Eric Larsen, and Rajat Taneja to its Board of Directors, effective November 13, 2026, increasing the board size from eight to eleven. The new directors bring expertise from LinkedIn, Visa, and healthcare advisory roles, with specific appointments to the Audit, Compensation, and Nominating committees. All three appointees were determined to be independent under NYSE rules.
Oscar Health Q3 2026 Results: Turns Profitable, Net Income $167M
For the three months ended September 30, 2026, Oscar Health reported total revenue of $5.14 billion, a significant increase from $2.99 billion in the prior year period. The company achieved earnings from operations of $178.0 million and net earnings before taxes of $175.4 million, representing a substantial turnaround from the operating loss of $129.3 million reported in the third quarter of 2025.
- Key figure
- Net income $167M
Oscar Health Financial Results
Oscar Health reported Q3 2026 financial results with total revenue of $5.14 billion, a significant increase from $2.99 billion in the prior year. The company achieved net income of $167.3 million compared to a net loss in Q3 2025 and raised its full-year 2026 earnings from operations outlook to a range of $850 million to $950 million.
- Term
- Q3 2026
“Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time. The ACA is the foundation of a rapidly-developing individual market in America, and Oscar Health is built to lead it. Our disciplined pricing, consumer-led products, and technology-powered approach are driving stronger economics and position us to grow market share and expand margin in 2027.”
Mark Bertolini, CEO of Oscar Health
Oscar Health Investor Presentation
Oscar Health is hosting its 2026 Investor Day to discuss its long-term strategy and financial targets. During the event, the company raised its full-year 2026 guidance for Earnings from Operations to a range of $600 million to $800 million and improved its Medical Loss Ratio outlook.
- Earnings call
- Sep 16, 2026, 9:00 AM ET